docetaxel anhydrous has been researched along with pr-104 in 1 studies
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (pr-104) | Trials (pr-104) | Recent Studies (post-2010) (pr-104) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 20 | 5 | 11 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
1 trial(s) available for docetaxel anhydrous and pr-104
Article | Year |
---|---|
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |